Methods and Compositions for Antibody Therapy

Abstract

Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on an FcγRIIA polymorphism, or an FcγRIIIA polymorphism, or both an FcγRIIA polymorphism and an FcγRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIIA polymorphism, or both the FcγRIIA polymorphism and the FcγRIIIA polymorphism.

What is claimed is: 
     
         1 . A method for predicting treatment response to an antibody therapy for a human test subject having an ADCC treatable disease or disorder, the method comprising:
 (a) classifying the test subject into one of nine genotype groups for the combination of H/R polymorphisms at amino acid position 131 of FcγRIIA receptor; and F/V polymorphisms at amino acid position 158 of FcγRIIIA receptor;   (b) using a reference index that correlates more than three categories of treatment response upon treatment with an antibody therapy with the genotype groups; and   (c) further comprising determining the ADCC function of the test subject.